Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent.
The HeLa cell line was created from cancerous cervical cells harvested from Henrietta Lacks, an African-American woman treated for cervical cancer at John Hopkins Hospital in Baltimore, Maryland in 1951. What makes the HeLa cell line so powerful are the cells’ ability to survive and reproduce indefinitely in lab conditions. Previous cells cultured from human cells would only live for a few days, whereas HeLa cells can be used for extensive studies due to their proliferation. HeLa cells have been behind some of the biggest medical advances in history, such as the development of a polio vaccine and in cancer studies.
As was common practice in the mid-20th century, Lacks was not informed of the cell harvesting, nor of their use in scientific studies. Her family was not made aware of their usage until the 1970s. Lacks eventually died of cervical cancer in 1951, aged 31. Her story continues to be a major example of privacy concerns and patient rights in medical research.
In their latest suit brough against Novartis and Viatris, the estate of Henrietta Lacks claims that the companies are unlawfully profiting from the use of HeLa cells in the creation of profitable drug products without gaining permission from or giving monetary compensation to her estate. Previous lawsuits from the estate were brought against companies such as Thermo Fisher and Ultragenyx, the former of which has since been settled. The estate claims that Novartis’ herpes drug Famvir, cancer treatment Kymriah, and spinal muscular atrophy therapy Zolgensma all used HeLa cells in their development and research. Viatris is being accused of misusing the cell line in the testing of herpes drug Denavir and depression treatment Mylan-Mirtazapine. Spokespeople for both companies declined to comment on the lawsuits.
The estate claim Lacks’ cells were exploited for research purposes and profited from by powerful organisations against her and her family’s will, and are requesting that any company profiting from commercialised products using HeLa cells be donated to her estate, and a court order blocking HeLa cell use without their permission.
Source:
Novartis, Viatris face new lawsuit over ‘HeLa’ cell misuse claims [Accessed August 6, 2024] https://www.reuters.com/legal/novartis-viatris-face-new-lawsuit-over-hela-cell-misuse-claims-2024-08-05/
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance